ASNS Overview

U.S. Stock Market Performance: U.S. stocks saw gains, with the Nasdaq Composite rising over 200 points, while the Dow and S&P 500 also experienced increases. Consumer discretionary shares rose by 2%, but energy stocks fell by 0.5%.

Inflation and Economic Indicators: U.S. inflation cooled to 2.7% in November, below expectations, boosting investor confidence in the Federal Reserve's easing cycle. Initial jobless claims decreased to 224,000, and the Philadelphia Fed Manufacturing Index fell significantly.

Notable Stock Movements: Athira Pharma's shares surged 84% after a development agreement, while Trump Media & Technology Group and FuelCell Energy also saw significant gains. Conversely, Insmed Inc and Pyxis Oncology experienced sharp declines in their stock prices.

Global Market Trends: European shares rose, with the eurozone's STOXX 600 gaining 0.56%, while Asian markets closed mixed, with Japan's Nikkei falling and China's Shanghai Composite rising slightly.

U.S. Stock Market Performance: U.S. stocks rose significantly, with the Dow Jones gaining approximately 400 points, while the NASDAQ and S&P 500 also saw notable increases.

Accenture's Strong Earnings: Accenture reported better-than-expected first-quarter results for 2026, with earnings of $3.94 per share and sales of $18.7 billion, surpassing analyst estimates.

Equities Movement: Athira Pharma's shares surged 88% following an acquisition announcement, while Mega Fortune Co Ltd and Pyxis Oncology saw significant declines of 59% and 54%, respectively.

Economic Indicators: The Philadelphia Fed Manufacturing Index fell sharply, initial jobless claims decreased, and the annual inflation rate dropped to 2.7%, the lowest since July.

Public Offering Details: Actelis Networks has priced a $5 million public offering, issuing 6.25 million shares and an equal number of common warrants at a combined price of $0.80 per unit.

Warrant Information: The warrants will have an exercise price of $0.80 and will be valid for five years.

Closing Date: The company expects the deal to close on December 19, 2025.

Use of Proceeds: Actelis plans to utilize the capital raised for general corporate purposes.